ARCHIVES

Proposed FDA Charges For NDA Drugs, Biologics Submissions Would Total $76 Million In FY 1990

This article is from The Cancer Letter archive.

Vol. 15 No. 04 | January 27, 1989

Download PDF Visit The Full Archive

Related Articles

In Brief: Kea, Montes Leave DCPC; Smart Heads Early Detection Branch; Costlow Special Assistant

October 3, 1986

NCI To Study Whether It Gets The Most From Advisors.

March 8, 2002

Tasigna Wins New Indication For CML; Jevtana Approved For Prostate Cancer

June 18, 2010

Fisher Files Motion In Database Flagging Suit; Documents Examine Role Of Former NCI Director Broder

October 20, 1995

Denosumab Demonstrates Superiority Over Zometa For Bone Metastases

August 28, 2009

NCI-Approved Clinical Trials

September 29, 2006